Last reviewed · How we verify
Placebo for dapagliflozin
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Used as control comparator in clinical trials for dapagliflozin efficacy evaluation.
At a glance
| Generic name | Placebo for dapagliflozin |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Therapeutic area | Control/Comparator |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In the context of dapagliflozin trials, placebo serves as the comparator arm to demonstrate that observed benefits are due to the active SGLT2 inhibitor, not expectation alone.
Approved indications
- Used as control comparator in clinical trials for dapagliflozin efficacy evaluation
Common side effects
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus (PHASE4)
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (PHASE2)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) (PHASE4)
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for dapagliflozin CI brief — competitive landscape report
- Placebo for dapagliflozin updates RSS · CI watch RSS
- AstraZeneca portfolio CI